European Field Study With Tepoxalin in Dogs Suffering From Disorders of Musculoskeletal System
World Small Animal Veterinary Association World Congress Proceedings, 2004
Goossens, Luc

This multicenter study was conducted in 6 European countries: Belgium, France, Germany, Great-Britain, Spain and the Netherlands. The study started in September 2002 and was evaluated in April 2004. Dogs suffering from acute or chronic disease of the musculoskeletal system were included.

Following a standardised two page data sheet which was translated in the respective local language, the following information was recorded:

 General Information (breed, age, sex, etc.)

 Case history

 Information on previous treatment and assessment thereof

 Clinical diagnosis

 Concomitant disease and treatment thereof

 Zubrin® treatment: 10 mg Tepoxalin / kg bwt orally, once daily

 Side effects and details if applicable

 Assessment of treatment success

 Owner feedback: Ease of Lyophilisate dosing

A total of 1294 cases could be evaluated. The mean age of the dogs included in the study was 7.6 years, the mean body weight 24.85 kg. The clinical diagnosis is given in Figure 1.


 

1.  Concomitant disease other than locomotory disorders was diagnosed in 302 dogs.

2.  50.4 % of the dogs were pre-treated with an NSAID or a corticosteroid.

3.  Duration of treatment with Zubrin® is given in Table 1.

Table 1: Duration of treatment with Zubrin®

Duration of treatment

% of dogs

1 -7 days

38.5 %

8 - 14 days

31 %

15 - 21 days

12.6 %

22 - 28 days

13.5 %

> 28 days

4.4 %

Treatment success was scored by the clinician with excellent or good in 78 % of the cases on Day 7, 81% on Day 14 and even 87% on Day 21.

Efficacy was also evaluated in 214 dogs on Day 7 and Day 28: Excellent scores increased from 14.5 % on Day 7 to 30.4% on Day 28. The data are given in Figure 2.

Figure 2: Evaluation of treatment success Day 7 - Day 28.


 

The ease of administration of Zubrin® lyophilisates was judged by the owner as excellent or good in 77.5 % of the dogs.

The most common adverse event reported was emesis in 3.9% of the cases followed by diarrhoea in 2.3% of the cases. Serious adverse events such as haemorrhagic diarrhoea were rare (0.23%).

From this study it can be concluded, that Zubrin® is an effective and safe NSAID for the treatment of musculoskeletal diseases in dogs, with very few serious side effects.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Luc Goossens


MAIN : Abstracts : Tepoxalin in Dogs
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27